Americas Association of Sarcoidosis and other granulomatous disorders 2024 conference highlights

Kristen Mathias; Anjali Wagle; Susana Dominguez-Peñuela; Carlos Pardo; Michelle Sharp; Nisha Gilotra

doi:10.36141/svdld.v42i3.17197

Americas Association of Sarcoidosis and other granulomatous disorders 2024 conference highlights

Authors

Kristen R. Mathias 1Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland
Anjali A. Wagle Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland
Susana Dominguez-Peñuela Division of Neuroimmunology, Department of Neurology, Johns Hopkins University School of Medicine, Baltimore
Carlos A. Pardo Division of Neuroimmunology, Department of Neurology, Johns Hopkins University School of Medicine, Baltimore
Michelle Sharp Division of Pulmonary and Critical Care, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore , Maryland
Nisha A. Gilotra Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland

Keywords:

: Sarcoidosis, Multidisciplinary Approach, Conference report, cardiomyopathy, precision medicine, granuloma, biomarkers, fibrosis, Health disparities

Abstract

The Americas Association of Sarcoidosis and Other Granulomatous Disorders (AASOG) 2024 conference, held in Baltimore, Maryland, leveraged a multidisciplinary approach to disseminating and addressing the latest updates, challenges and opportunities in multisystemic sarcoidosis. The conference, aptly titled “The Art of Working Together for Progress,” featured insights from diverse perspectives in sarcoidosis both nationally and internationally. This review summarizes the key takeaways from the six conference sessions: I. Sarcoidosis Multidisciplinary Care, II. Health Disparities in Sarcoidosis, III. The Search for Precision in Sarcoidosis, IV. Clinical Outcomes in Sarcoidosis, V. Clinical Trials in Sarcoidosis, and VI. Advanced Disease in Sarcoidosis.

References

1. Arger N, Sharp M, Bonham C, Patel D, Gupta R, James WE. Sarcoidosis Faculty Development: The Pipeline Is Running Dry. Chest. 2024 Sep;166(3):528-531. doi: 10.1016/j.chest.2024.03.039. Epub 2024 Mar 26. PMID: 38548100; PMCID: PMC11904606.

2. Sharp M, Eakin MN, Drent M. Socioeconomic determinants and disparities in sarcoidosis. Curr Opin Pulm Med. 2020 Sep;26(5):568-573. doi: 10.1097/MCP.0000000000000704. PMID: 32732595.

3. Gwadera Ł, Białas AJ, Górski W, et al. Gender differences in health-related quality of life measured by the Sarcoidosis Health Questionnaire. Sci Rep. 2021 May 13;11(1):10242. doi: 10.1038/s41598-021-89383-1. PMID: 33986317; PMCID: PMC8119441.

4. Arkema EV, Eklund A, Grunewald J, Bruze G. Work ability before and after sarcoidosis diagnosis in Sweden. Respir Med. 2018 Nov;144S:S7-S12. doi: 10.1016/j.rmed.2018.09.016. Epub 2018 Oct 5. PMID: 30343984.

5. Lundkvist A, Kullberg S, Arkema EV, et al. Differences in disease presentation between men and women with sarcoidosis: A cohort study. Respir Med. 2022 Jan;191:106688. doi: 10.1016/j.rmed.2021.106688. Epub 2021 Nov 23. PMID: 34839065.

6. Rossman MD, Thompson B, Frederick M, et al; ACCESS Group. HLA and environmental interactions in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2008 Dec;25(2):125-32. PMID: 19382531.

7. Li J, Yang J, Levin AM, Montgomery CG, et al. Efficient generalized least squares method for mixed population and family-based samples in genome-wide association studies. Genet Epidemiol. 2014 Jul;38(5):430-8. doi: 10.1002/gepi.21811. Epub 2014 May 20. PMID: 24845555; PMCID: PMC4112407.

8. Rivera NV, Patasova K, Kullberg S, et al. A Gene-Environment Interaction Between Smoking and Gene polymorphisms Provides a High Risk of Two Subgroups of Sarcoidosis. Sci Rep. 2019 Dec 9;9(1):18633. doi: 10.1038/s41598-019-54612-1. PMID: 31819081; PMCID: PMC6901455.

9. Yang IV, Konigsberg I, MacPhail K, et al. DNA Methylation Changes in Lung Immune Cells Are Associated with Granulomatous Lung Disease. Am J Respir Cell Mol Biol. 2019 Jan;60(1):96-105. doi: 10.1165/rcmb.2018-0177OC. PMID: 30141971; PMCID: PMC6348713.

10. Konigsberg IR, Maier LA, Yang IV. Epigenetics and sarcoidosis. Eur Respir Rev. 2021 Jun 23;30(160):210076. doi: 10.1183/16000617.0076-2021. PMID: 34168064; PMCID: PMC9488730.

11. Wahlström J, Katchar K, Wigzell H, Olerup O, Eklund A, Grunewald J. Analysis of intracellular cytokines in CD4+ and CD8+ lung and blood T cells in sarcoidosis. Am J Respir Crit Care Med. 2001 Jan;163(1):115-21. doi: 10.1164/ajrccm.163.1.9906071. PMID: 11208635.

12. Siltzbach LE. The Kveim test in sarcoidosis. A study of 750 patients. JAMA. 1961 Nov 4;178:476-82. doi: 10.1001/jama.1961.03040440028006. PMID: 13912868.

13. Ramstein J, Broos CE, Simpson LJ, et al. IFN-γ-Producing T-Helper 17.1 Cells Are Increased in Sarcoidosis and Are More Prevalent than T-Helper Type 1 Cells. Am J Respir Crit Care Med. 2016 Jun 1;193(11):1281-91. doi: 10.1164/rccm.201507-1499OC. PMID: 26649486; PMCID: PMC4910899.

14. Chen ES, Song Z, Willett MH, et al. Serum amyloid A regulates granulomatous inflammation in sarcoidosis through Toll-like receptor-2. Am J Respir Crit Care Med. 2010 Feb 15;181(4):360-73. doi: 10.1164/rccm.200905-0696OC. Epub 2009 Nov 12. PMID: 19910611; PMCID: PMC2822973.

15. Crouser ED, Locke LW, Julian MW, et al. Phagosome-regulated mTOR signalling during sarcoidosis granuloma biogenesis. Eur Respir J. 2021 Mar 18;57(3):2002695. doi: 10.1183/13993003.02695-2020. PMID: 32943400.

16. Broos CE, Koth LL, van Nimwegen M, et al. Increased T-helper 17.1 cells in sarcoidosis mediastinal lymph nodes. Eur Respir J. 2018 Mar 1;51(3):1701124. doi: 10.1183/13993003.01124-2017. PMID: 29449421.

17. Ochoa D, Karim M, Ghoussaini M, Hulcoop DG, McDonagh EM, Dunham I. Human genetics evidence supports two-thirds of the 2021 FDA-approved drugs. Nat Rev Drug Discov. 2022 Aug;21(8):551. doi: 10.1038/d41573-022-00120-3. PMID: 35804044.

18. Garman L, Pezant N, Dawkins BA, et al. Inclusivity in Research Matters: Variants in PVT1 Specific to Persons of African Descent Are Associated with Pulmonary Fibrosis. Am J Respir Crit Care Med. 2024 Jan 1;209(1):106-109. doi: 10.1164/rccm.202210-1969LE. Erratum in: Am J Respir Crit Care Med. 2024 May 15;209(10):1286. doi: 10.1164/rccm.v209erratum6. PMID: 37348127; PMCID: PMC10870883.

19. Dawkins BA, Garman L, Cejda N, et al. Novel HLA associations with outcomes of Mycobacterium tuberculosis exposure and sarcoidosis in individuals of African ancestry using nearest-neighbor feature selection. Genet Epidemiol. 2022 Oct;46(7):463-474. doi: 10.1002/gepi.22490. Epub 2022 Jun 14. PMID: 35702824; PMCID: PMC10237150.

20. Lockstone HE, Sanderson S, Kulakova N, et al. Gene set analysis of lung samples provides insight into pathogenesis of progressive, fibrotic pulmonary sarcoidosis. Am J Respir Crit Care Med. 2010 Jun 15;181(12):1367-75. doi: 10.1164/rccm.200912-1855OC. Epub 2010 Mar 1. PMID: 20194811.

21. Su R, Li MM, Bhakta NR, et al. Longitudinal analysis of sarcoidosis blood transcriptomic signatures and disease outcomes. Eur Respir J. 2014 Oct;44(4):985-93. doi: 10.1183/09031936.00039714. Epub 2014 Aug 19. PMID: 25142485.

22. Koth LL, Solberg OD, Peng JC, Bhakta NR, Nguyen CP, Woodruff PG. Sarcoidosis blood transcriptome reflects lung inflammation and overlaps with tuberculosis. Am J Respir Crit Care Med. 2011 Nov 15;184(10):1153-63. doi: 10.1164/rccm.201106-1143OC. Epub 2011 Aug 18. PMID: 21852540; PMCID: PMC3262024.

23. Bhargava M, Viken KJ, Barkes B, et al. Novel protein pathways in development and progression of pulmonary sarcoidosis. Sci Rep. 2020 Aug 6;10(1):13282. doi: 10.1038/s41598-020-69281-8. PMID: 32764642; PMCID: PMC7413390.

24. Crouser ED, Julian MW, Locke LW, et al. The Renin-Angiotensin-Aldosterone System Regulates Sarcoidosis Granulomatous Inflammation. Am J Respir Crit Care Med. 2024 Aug 15;210(4):497-507. doi: 10.1164/rccm.202402-0265OC. PMID: 38941161; PMCID: PMC11351795.

25. Reyfman PA, Walter JM, Joshi N, et al. Single-Cell Transcriptomic Analysis of Human Lung Provides Insights into the Pathobiology of Pulmonary Fibrosis. Am J Respir Crit Care Med. 2019 Jun 15;199(12):1517-1536. doi: 10.1164/rccm.201712-2410OC. PMID: 30554520; PMCID: PMC6580683.

26. Obi ON, Saketkoo LA, Russell AM, Baughman RP. Sarcoidosis: Updates on therapeutic drug trials and novel treatment approaches. Front Med (Lausanne). 2022 Oct 12;9:991783. doi: 10.3389/fmed.2022.991783. PMID: 36314034; PMCID: PMC9596775.

27. Saketkoo LA, Russell AM, Jensen K, et al. Health-Related Quality of Life (HRQoL) in Sarcoidosis: Diagnosis, Management, and Health Outcomes. Diagnostics (Basel). 2021 Jun 15;11(6):1089. doi: 10.3390/diagnostics11061089. PMID: 34203584; PMCID: PMC8232334.

28. Yang J, Hanna-Pladdy B, Gruber-Baldini AL, et al. Response shift - The experience of disease progression in Parkinson disease. Parkinsonism Relat Disord. 2017 Mar;36:52-56. doi: 10.1016/j.parkreldis.2016.12.027. Epub 2016 Dec 29. PMID: 28082015.

29. Morimoto R, Unno K, Fujita N, et al. Prospective Analysis of Immunosuppressive Therapy in Cardiac Sarcoidosis With Fluorodeoxyglucose Myocardial Accumulation: The PRESTIGE Study. JACC Cardiovasc Imaging. 2024 Jan;17(1):45-58. doi: 10.1016/j.jcmg.2023.05.017. Epub 2023 Jul 12. PMID: 37452820.

30. Birnie D, Beanlands RSB, Nery P, et al. Cardiac Sarcoidosis multi-center randomized controlled trial (CHASM CS- RCT). Am Heart J. 2020 Feb;220:246-252. doi: 10.1016/j.ahj.2019.10.003. Epub 2019 Oct 20. PMID: 31911261; PMCID: PMC7367280.

31. Kron J, Crawford T, Mihalick V, et al. Interleukin-1 blockade in cardiac sarcoidosis: study design of the multimodality assessment of granulomas in cardiac sarcoidosis: Anakinra Randomized Trial (MAGiC-ART). J Transl Med. 2021 Nov 8;19(1):460. doi: 10.1186/s12967-021-03130-8. PMID: 34749739; PMCID: PMC8575149.

32. Scadding JG. Prognosis of intrathoracic sarcoidosis in England. A review of 136 cases after five years' observation. Br Med J. 1961 Nov 4;2(5261):1165-72. doi: 10.1136/bmj.2.5261.1165. PMID: 14497750; PMCID: PMC1970202.

33. Obi ON, Alqalyoobi S, Maddipati V, Lower EE, Baughman RP. High-Resolution CT Scan Fibrotic Patterns in Stage IV Pulmonary Sarcoidosis: Impact on Pulmonary Function and Survival. Chest. 2024 Apr;165(4):892-907. doi: 10.1016/j.chest.2023.10.021. Epub 2023 Oct 23. PMID: 37879560.

34. Judson MA, Boan AD, Lackland DT. The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States. Sarcoidosis Vasc Diffuse Lung Dis. 2012 Oct;29(2):119-27. PMID: 23461074.

35. Patterson KC, Strek ME. Pulmonary fibrosis in sarcoidosis. Clinical features and outcomes. Ann Am Thorac Soc. 2013 Aug;10(4):362-70. doi: 10.1513/AnnalsATS.201303-069FR. PMID: 23952859.

36. Reich JM. Mortality of intrathoracic sarcoidosis in referral vs population-based settings: influence of stage, ethnicity, and corticosteroid therapy. Chest. 2002 Jan;121(1):32-9. doi: 10.1378/chest.121.1.32. PMID: 11796429.

37. Flaherty KR, Wells AU, Cottin V, et al; INBUILD Trial Investigators. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med. 2019 Oct 31;381(18):1718-1727. doi: 10.1056/NEJMoa1908681. Epub 2019 Sep 29. PMID: 31566307.

38. Sheikh FH, Craig PE, Ahmed S, et al. Characteristics and Outcomes of Patients with Inflammatory Cardiomyopathies Receiving Mechanical Circulatory Support: An STS-INTERMACS Registry Analysis. J Card Fail. 2022 Jan;28(1):71-82. doi: 10.1016/j.cardfail.2021.07.025. Epub 2021 Aug 30. PMID: 34474157.

39. Crawford TC, Okada DR, Magruder JT, et al. A Contemporary Analysis of Heart Transplantation and Bridge-to-Transplant Mechanical Circulatory Support Outcomes in Cardiac Sarcoidosis. J Card Fail. 2018 Jun;24(6):384-391. doi: 10.1016/j.cardfail.2018.02.009. Epub 2018 Mar 1. PMID: 29482029.

40. Gupta R, Bermudez F, Vora T, et al. Surveillance Imaging and Management of Cardiac Sarcoidosis After Advanced Heart Failure Therapies. Am J Cardiol. 2024 Jul 1;222:35-38. doi: 10.1016/j.amjcard.2024.04.033. Epub 2024 Apr 23. PMID: 38663574.

41. Luk A, Lee A, Ahn E, Soor GS, Ross HJ, Butany J. Cardiac sarcoidosis: recurrent disease in a heart transplant patient following pulmonary tuberculosis infection. Can J Cardiol. 2010 Aug-Sep;26(7):e273-5. doi: 10.1016/s0828-282x(10)70424-4. PMID: 20847976; PMCID: PMC2950734.

42. Henderson AD, Tian J, Carey AR. Neuro-Ophthalmic Manifestations of Sarcoidosis. J Neuroophthalmol. 2021 Dec 1;41(4):e591-e597. doi: 10.1097/WNO.0000000000001108. PMID: 33110001.

43. Stern BJ, Royal W 3rd, Gelfand JM, et al. Definition and Consensus Diagnostic Criteria for Neurosarcoidosis: From the Neurosarcoidosis Consortium Consensus Group. JAMA Neurol. 2018 Dec 1;75(12):1546-1553. doi: 10.1001/jamaneurol.2018.2295. PMID: 30167654.

44. El Sammak S, Lec BM, Bou GA, Wagstaff WV, Lawson EC, Hutto SK. Hydrocephalus in Neurosarcoidosis: Clinical Course, Radiographic Accompaniments, and Experience with Shunting. Mult Scler Relat Disord. 2023 Nov;79:105040. doi: 10.1016/j.msard.2023.105040. Epub 2023 Sep 28. PMID: 37783195.

45. Murphy OC, Salazar-Camelo A, Jimenez JA, et al. Clinical and MRI phenotypes of sarcoidosis-associated myelopathy. Neurol Neuroimmunol Neuroinflamm. 2020 Apr 8;7(4):e722. doi: 10.1212/NXI.0000000000000722. PMID: 32269072; PMCID: PMC7176244.

46. Barreras P, Stern BJ. Clinical features and diagnosis of neurosarcoidosis - review article. J Neuroimmunol. 2022 Jul 15;368:577871. doi: 10.1016/j.jneuroim.2022.577871. Epub 2022 Apr 18. PMID: 35523055.

47. Kreß L, Egenolf N, Sommer C, Üçeyler N. Cytokine expression profiles in white blood cells of patients with small fiber neuropathy. BMC Neurosci. 2023 Jan 5;24(1):1. doi: 10.1186/s12868-022-00770-4. PMID: 36604634; PMCID: PMC9817338.

48. Uçeyler N, Kafke W, Riediger N, et al. Elevated proinflammatory cytokine expression in affected skin in small fiber neuropathy. Neurology. 2010 Jun 1;74(22):1806-13. doi: 10.1212/WNL.0b013e3181e0f7b3. PMID: 20513817.

49. Tavee JO, Karwa K, Ahmed Z, Thompson N, Parambil J, Culver DA. Sarcoidosis-associated small fiber neuropathy in a large cohort: Clinical aspects and response to IVIG and anti-TNF alpha treatment. Respir Med. 2017 May;126:135-138. doi: 10.1016/j.rmed.2017.03.011. Epub 2017 Mar 9. PMID: 28318820.

50. Raasing L, Vogels OJM, Veltkamp M, Grutters JC. Infliximab decreases inflammatory activity but has no effect on small fiber neuropathy related symptoms in Dutch patients with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2022 Dec 19;39(4):e2022033. doi: 10.36141/svdld.v39i4.12031. PMID: 36533604; PMCID: PMC9798340.

51. Møller J, Hilberg O, Bendstrup E. Fatigue in Patients with Sarcoidosis in Denmark. Lung. 2023 Feb;201(1):103-110. doi: 10.1007/s00408-023-00602-0. Epub 2023 Feb 11. PMID: 36773043.

52. Zieleźnik K, Jastrzębski D, Ziora D. Fatigue in patients with inactive sarcoidosis does not correlate with lung ventilation ability or walking distance. Pilot Study. Pneumonol Alergol Pol. 2015;83(1):14-22. doi: 10.5603/PiAP.2015.0002. PMID: 25577529.